Evidence types
Systematic review and meta-analysis articles covering combined evidence from multiple IBD studies. Research context emphasizes studies, trials, biomarkers, mechanisms, and emerging IBD science.
Page 1 of 3 · 141 articles
Distinguishing Crohn’s disease from intestinal tuberculosis can change treatment (immune suppression versus anti‑tubercular therapy) and outcomes. This review summarizes which findings have tended to favor one diagnosis...
People with IBD may be interested because the review summarizes biological pathways that could link gut inflammation to brain changes seen in Alzheimer’s disease, suggesting possible shared mechanisms and future research...
IBD-U means no clear Crohn’s or ulcerative colitis diagnosis yet — that uncertainty can affect treatment decisions and follow-up. The review highlights tests that may help clarify diagnosis and stresses that many...
People with UC often look for dietary supplements or ‘‘natural’’ add-ons. This review explains which nutraceutical approaches have the most and least clinical support, helping patients and clinicians weigh potential...
Pharmacokinetics affect how well biologic drugs work for IBD. Better PK data could help explain why many patients have inadequate responses and could inform personalized dosing for IL-23p19 inhibitors used in Crohn’s...
Understanding how different forms of programmed cell death in the gut lining contribute to barrier loss and inflammation could point to new therapeutic targets for IBD. The review also flags natural products and...
People with IBD and coexisting primary sclerosing cholangitis (PSC) may get faecal calprotectin tests to monitor colon inflammation. If PSC raises FC independently of colitis, FC could mislead decisions about IBD...
Improving nursing support during IBD trial pathways could help people stay engaged, understand what participation involves, and report problems earlier—potentially making trials safer and more equitable.
The article reviews current and emerging IBD treatments and the biological reasons they may work — useful for patients wanting to understand treatment options and future directions. It highlights therapies beyond...
People with IBD or Crohn's disease considering or taking upadacitinib may worry about rare but serious risks such as heart attacks, strokes, or blood clots. This meta-analysis found no clear increase in those events...
Microbiota-targeting treatments are an active area of IBD research, and biomaterials may help overcome delivery challenges that limit current microbiome therapies. Advances here could improve how well these approaches...
The review shows psychotherapies can improve quality of life and reduce anxiety and depression in people with IBD, outcomes that matter for daily functioning even when intestinal symptoms may not change.
Dietary patterns like the Mediterranean diet may reduce inflammation and improve quality of life for people with Crohn’s disease by beneficially altering the gut microbiome and inflammatory markers. That could offer a...
The review explains why many patients still fail current therapies and summarizes promising new research directions (microRNA, microbiome therapies, stromal cell approaches) that could change treatment strategies.
People with ulcerative colitis face a higher colorectal cancer risk driven in part by chronic inflammation; this review explains the molecular and immune mechanisms behind that risk and highlights biomarkers and...
The review connects animal-model discoveries (IL-23/IL-17 and TNF pathways, gut–joint interactions) to therapies and research priorities relevant to people with SpA and IBD-associated arthritis.
People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.
People with IBD may be interested because probiotics are being explored as a safer, non-immunosuppressive approach to help modulate gut microbiota and reduce inflammation, but effective oral delivery remains a key...
Extraintestinal symptoms such as fatigue and joint pain significantly affect quality of life in Crohn's disease. This review suggests ustekinumab may help reduce fatigue and arthritis/arthralgia more than TNF antagonists...
Many people with IBD try dietary changes to manage symptoms. This review summarizes what published adult studies report and points toward whole-food and Mediterranean-style patterns as commonly supported approaches.
For people hospitalized with acute severe ulcerative colitis, starting a JAK inhibitor together with IV steroids right away (rather than waiting for steroids to fail) could potentially control inflammation sooner and...
This review may help patients and clinicians understand how long-lasting changes in bacterial metabolism could contribute to IBD relapse and point toward future microbiome-targeted therapies aimed at restoring resilient...
Vitamin D appears linked to immune regulation, gut barrier health, and the microbiome—processes relevant to IBD and other intestinal disorders. Understanding this could affect how clinicians monitor and study vitamin D...
This review highlights a potential new class of IBD drugs (RIPK1 inhibitors) that target inflammatory and cell-death pathways implicated in epithelial injury. For people with IBD, it signals an area of active research...
People labelled with IBS-D may actually have treatable organic conditions that require different tests and treatments; avoiding diagnostic mistakes can speed appropriate care and reduce unnecessary symptom-focused...
Understanding how the gut virome shapes regulatory T cells could reveal new biomarkers or therapeutic targets for IBD and related systemic immune diseases. This may help explain unexplained flares or individual...
Biologics and newer small molecules have markedly changed IBD care and outcomes for many patients, but their population-level impact depends on access, cost, and how they are used. Understanding this helps patients and...
This study addresses whether being on biologic or small‑molecule IBD drugs before colorectal surgery affects short‑term postoperative complications — a practical concern for patients and clinicians planning surgery.
Rising incidence in east and southeast Asia means more people will live with IBD over coming decades, which affects healthcare planning, access to specialists, and resource needs. Understanding regional trajectories can...
Depressive disorders—diagnosed using structured clinical interviews—appear to be relatively common in people with IBD, which has implications for screening and referral to mental health care within IBD clinics.
Bile acids shaped by gut microbes can influence inflammation and metabolism, so understanding these pathways could lead to new biomarkers or treatments relevant to people with IBD.
If you have IBD, the mouth and gums may be part of shared inflammatory pathways with your gut. Periodontitis is associated with higher odds of having IBD in cross-sectional studies and has a modest link to later...
Identifies factors that may raise the chance of developing pouchitis after IPAA — useful for patients considering or recovering from proctocolectomy and for clinicians planning perioperative care or monitoring.
Smart, stimuli-responsive nanocarriers could one day allow IBD treatments to act more precisely in the gut and limit side effects; that may matter to people hoping for better-targeted therapies or fewer systemic...
This review suggests Aloe vera polysaccharides could support gut barrier repair, microbiome balance, and immune regulation—mechanisms relevant to IBD inflammation and healing. However, evidence is mainly preclinical and...
Nanotechnology approaches aim to improve how cytokine-targeting therapies are delivered in IBD, which could reduce systemic exposure and immunogenicity and increase local effectiveness.
This review pools available human and animal studies on sodium butyrate for ulcerative colitis and highlights promising signals—especially for oral microencapsulated formulations—while noting that clinical evidence is...
Keratoconus can threaten vision; identifying risk factors helps clinicians and patients consider prevention, early detection, and targeted eye care. Some commonly encountered issues in people with IBD—like dry eye or...
This review organizes and grades causal evidence linking individual gut bacteria, their metabolites, and host pathways in IBD—helping researchers and clinicians see which microbe–metabolite mechanisms are best supported...
People with Crohn's disease or ulcerative colitis might see more AI-based prognostic tools in the literature, but this review shows most models are not yet proven ready for clinical use because they lack key validation...
A Cochrane network meta-analysis compares many biologic medicines used for Crohn’s disease, which can help patients and clinicians understand how different drugs and drug classes stack up for inducing and keeping...
RDW is a cheap, routinely measured blood parameter; if it reliably reflects IBD presence or activity, it could be an easy additional tool to help detect flares or support assessment without extra testing.
Dysplasia is the key premalignant change that raises colorectal cancer risk in people with colonic IBD. Better detection and clearer management pathways can reduce cancer risk and help patients avoid unnecessary surgery.
If you have IBD and take biologic therapy plus other medicines, inflammation and anti-cytokine treatment may change how your other drugs are metabolized. This review discusses ways researchers are trying to predict and...
People with IBD are often interested in new, less toxic therapies that restore gut health. PEVs are an emerging microbiome-based approach that could one day offer targeted immune and barrier benefits without live...
The review connects microbiome-targeted therapies (diet, probiotics, FMT, antibiotics, and newer approaches) to mechanisms relevant to IBD and systemic health, highlighting why these strategies are of interest to...
Sarcopenia or low muscle mass may be linked with worse endoscopic healing and reduced durability of biologic therapy in IBD, particularly Crohn's disease, which could matter for prognosis and treatment planning if...
This review links lactic acid bacteria ecology in engineered communities to potential applications in gut health and IBD research, which could guide future microbiome-based interventions.
